A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2017
At a glance
- Drugs Cediranib (Primary) ; Olaparib (Primary) ; Carboplatin; Cisplatin; Etoposide
- Indications Neuroendocrine carcinoma; Small cell lung cancer
- Focus Therapeutic Use
- 29 May 2017 Status changed from recruiting to suspended.
- 11 Apr 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Apr 2020.
- 11 Apr 2017 Status changed from not yet recruiting to recruiting.